

101 Rec'dect/PTO 04 JUN 2002

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

.					
Substitute	for form 1449A/P1	ro		C	omplete if Known
				Application Number	10/049,868
INFO	RMATION	VDI:	SCLOSURE	Filing Date	February 11, 2002
STAT	EMENTE	BY A	PPLICANT	First Named Inventor	Hans Deckmyn and Nancy Cauwenberghs
			•	Group Art Unit	1644
(L	ise as many she	eets as	necessary)	Examiner Name	
Sheet	1	of	2	Attorney Docket Number	522-1778

U.S. PATENT DOCUMENTS							
Examiner nitials	Cite No. ¹	U.S. Patent Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
MH	٨ı	5,336,667		Kirby	08-09-1994		
MH	AZ	5,486,361		Gralnick	01-23-1996		
,							
					 		
	•						
	•	,					
			-				
				•			
i					<u> </u>		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	Office	Foreign Patent Doc Number ⁴	ument Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T _Q
m#	BI		WO-00/26667-A1		Miller	05-11-2000		
								-
	·					 		
				 				
				1166				

Examiner Signature	Maher	Hereldad	Date Considered	10/21/04
Signature	-		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. See attached Kinds of U.S. Patent Documents. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00)
Please type a plus sign (+) inside this box + +

Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/049,868	
INFO	RMATI	ONDIS	CLOSURE	Filing Date	February 11, 2002	
STAT	TEMEN'	TRY AF	PLICANT	First Named Inventor	Hans Deckmyn and Nancy Cauwenberghs	
				Group Art Unit	1644	
	(use as mai	ny sheets as r	necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	522-1778	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MH	C١	Reverter, "Inhibition of Platelet - mediated, Tissue Factor induced", J. Clin. Invest, vol a8, no. 3, 8/96,pp 863-874	
MH	cz	Pareti, "Interaction of porcine von Willebrand factor with the platelet", British J. of Haematology, vol 82, 1992, pp 81 - 86	
m#	C3	Becker, "Effects of an Antiplatlet Glycoprotein Ib Antibody on", Blood, vol 74, no.2, 8/1/89, pp 690-694	
MH	Cif	Ward, "Epitope and functional characterization of the CD42", Platlet antigens, pp 1336-1337	
MH	c5	Cowenberghs, "Antithrombotic Effect of Platelet Glycoprotein Ib- Blocking", Arteriosclerosis, Thrombosis abd Vascular Biology,"	
M 14	cı	Coller, "A Murine Monoclonal Antibody that Completely Blocks", J. Clin. Invest. vol 72, 7/83, pp 325-338	
mH	C7.	Shetler, "Antithrombotic Assessment of the Effects of Combination", 1996, American Heart Association, pp 1719 - 1725	
mth	C8	Simoons, "Randomized Trial of a GPIIb/IIIa Platelet Receptor", Circulation, vol 89, no2, 2/94, pp 596 - 603	
mH	c9	Schultz, "Use of C7E3 Fab in Conjunction With Primary Coronary", Catherization and Coardiovascular Diagnosis, vol 39, 1996, pp 143 - 148	
mth	CIO	Lincoff, "Platelet Glycoprotein IIb/IIIa Receptor Blocade And", New England J. of Med., vol 336, no 24, 6/12/97, pp 1689-1697	,
my	CH	Gold, "PharmacodynamicStudy of F (ab)2 Fragments of", J. Clin. Invest., vol 86, 8/90, pp 651 - 659, 19 90	

Examiner Signature Maher Haddad Considered 10/21/04	f
---	---

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information nless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1 Complete if Known Substitute for form 1449A/PTO **Application Number** INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT **First Named Inventor** Hans Deckmyn 1644 Art Unit (use as many sheets as necessary) **Examiner Name** 2 Attorney Docket Number of 522-1778 Sheet

			U.S. PAT	TENT DOCUMENTS	
		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant
Examiner Initials*	Cite No.1	Number Kind Code (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear
		US- 5,336,667 R1	08 09 1994	- Kirkby-	
		US 5,486,361 B1	01-23-1996	Grainick	
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			
		US-		,	
		US-			
		US-		·	
		U\$-			
		US-			
		US-		,	
		US-	-		
		ŲS-	•		
		US-	١		
		US-			
·		US-			
		US-			
		US-			

				FOR	EIGN PATENT DO	CUMENTS		
	Cita		Foreign Patent Do	cument	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind ⁵ (if known)		Applicant of Cited Document	Passages or Relevant Figures Appear	Te
		wo e	00/26667-	A1	-05-11-2000	Willer		
	· · ·							_
								
			-					-
-								
	···							+-
	·		•	+ +				+

Examiner	NA 1		Date	15/1
Signature	Maker	Haddad	Considered	10/21/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	PTO/\$B/08B (
d for use through	10/31/2002. OMB 065	1-003

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Tradeposity Office: U.S. DEPARTMENT OF COMMERCE umber.

522-1778

Under the Paperwork Reduction Act of the no persons are require	ed to respond to a collection of inf	n unless it contains a valid OMB control nu			
	Complete if Known				
Substitute for form 1449B/PTO	Application Number	10/04986			
INFORMATION DISCLOSURE	Filing Date	JC11 Rec'd PCT/PTO P10F			
STATEMENT BY APPLICANT	First Named Inventor	Hans Deckmyn			
STATEMENT BY APPLICATION	Group Art Unit				

(use as many sheets as necessary)

of

Sheet

Examiner Name

Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	T
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	12
		Pareti, "Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex", British Journal of Haematology, vol 82, 1992, pp 81-86	
	-	Becker, "Effects of Antiplatelet Glycoprotein Ib Antibody on Hemostatic Function in the Guinea Pig", Blood, vol 74, No 2, 8/1/89, pp 690-694.	
•	-	Ward, "Epitope and functional characterization of the CD42 (gplb/IX) mAb panel", Platelet antigens, pp 1336-1337	
		Cauwenberghs, "Antithrombotic Effect of Platelet Glycoprotein Ib - Blocking Monoclonal Antibody Fab - Eragments in Nonhuman Primates", Arterioscler Thromb Vasc Biol., 1/4/2000, pp 1347-1353	
 			
			+
	!		
			<u>_</u> _
Examine Signatur	er e	Maken Haddad Considered 15/21/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

²Applicant is to place a check mark here if English language Translation is attached. ¹ Applicant's unique citation designation number (optional).